AURA Stock Analysis: Buy, Sell, or Hold?
AURA - Aura Biosciences, Inc. Common Stock
$5.94
0.06 (1.02%)
▲
5d:
+4.95%
30d:
+12.08%
90d:
-3.1%
BUY
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Mar 23, 2026
Get Alerted When AURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AURA is currently trading at $5.94, which is considered extended relative to its 30-day fair value range of $5.13 to $5.69.
Technical Outlook: Technically, AURA is in a downtrend. Immediate support is located at $4.97, while resistance sits at $6.15.
Market Sentiment: AURA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.40 (+226.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AURA is in a downtrend. Immediate support is located at $4.97, while resistance sits at $6.15.
Market Sentiment: AURA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.40 (+226.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$5.13 -
$5.69
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 226.6% below Wall St target ($19.40)
Fair Price Analysis
30-Day Fair Range
$5.13 -
$5.69
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.75
(12.7%)
Support & Resistance Levels
Support Level
$4.97
Resistance Level
$6.15
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-3.19
Wall Street Target
$19.40
(+226.6%)
Last updated: February 03, 2026 5:16 PM ET
Data refreshes hourly during market hours. Next update: 6:16 PM
Data refreshes hourly during market hours. Next update: 6:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AURA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Plavsic
SELL
12169 shares
2025-10-16
Amy Elazzouzi
SELL
7722 shares
2025-08-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 54 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 56 HOLD |
